Hi Vapor, of the three; Salesman, Deal maker and Visionary, only shines in the third aspect, and that gets undermined to a large degree because that Vision has been way over under delivered.
Salesman: has failed to elicit any significant interest from RIs, on the level of tiny. All here should realise the import of that.
Makes promises that, up to date, are hugely ‘misleading’.
One year ago, on that Pro video, WP would have been better of suggesting; we hope to get to a level where our internal valuation will be $40 plus, instead of ‘our’ internal valuation is $40 plus.
One billion dollars is not enough to buy this company, have been better of suggesting; this has the potential to be of a value of one billion dollars plus, as the science progresses towards 2025.
Commercialisation in 2025; been better off suggesting that ‘by’ 2025 would be getting well and truly on track to commercialisation.
Nasdaq listing; alluded to being way closer than the reality; better of saying: once on track to that 2025 date Nasdaq listing should well and truly prime its listing on the said Market.
Allusions to interest from third parties; have suggested that by 2025 or thereabouts should generate significant interest from potential suitors.
Have way over promised and way too far lifted the expectations of any RIs, virtually set themselves to fail by not tempering that sales pitch.
Deal maker, no where near so, the ideal deal, 100%, would not have included the options overhang. 10% placement acceptable.
Anteris has zero clout, otherwise the option offer would not have been granted, it has been done before.
No offer or partnership deal been made.
Virtually the only liquidity is being generated by the ceasing and becoming Ann’s, that at the cost of inhibiting the appreciation of the sp.
Visionary; high on Vision, low on delivery, as per illustrated above. The only thing holding it together in the interim is the actual ‘measurable’ attributes of the Science, yet even that fails to ignite the fortunes of this Company.
25-30 fold increase; is this for real; a 8 billon dollar company in the next 2 1/2 years with commercialisation still 2 years plus away.
In five years the sp at $4 400!, have I read this right, 200 times $22.
My expectations way more tempered, at this time a one billion dollar MC still might be pie in the sky, only a offer in the wings will generate that.
Imho.
- Forums
- ASX - By Stock
- AVR
- Ann: Latest Patient Group Show Best Results to Date at 30 Days
AVR
anteris technologies global corp.
Add to My Watchlist
6.60%
!
$6.30

Ann: Latest Patient Group Show Best Results to Date at 30 Days, page-45
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.30 |
Change
0.390(6.60%) |
Mkt cap ! $97.48M |
Open | High | Low | Value | Volume |
$5.93 | $6.30 | $5.91 | $98.54K | 15.86K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2062 | $6.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.30 | 463 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2062 | 6.150 |
1 | 3500 | 6.120 |
1 | 296 | 6.110 |
1 | 2000 | 6.100 |
1 | 1000 | 6.000 |
Price($) | Vol. | No. |
---|---|---|
6.300 | 463 | 1 |
6.320 | 7 | 1 |
6.370 | 3 | 1 |
6.400 | 130 | 1 |
6.500 | 255 | 1 |
Last trade - 14.19pm 27/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online